دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials
Manasi Agrawal, MD, Francesca Petralia, PhD, Adam Tepler, MD, Laura Durbin, MS, Walter Reinisch, MD, Jean-Frederic Colombel, MD, Shailja C Shah, MD, MPH
doi : 10.1093/ibd/izac067
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 1–8
Gender-based differences are reported in inflammatory bowel diseases (IBD) pathogenesis, but their impacts on IBD outcomes are not well known. We determined gender-based differences in response to treatment with tumor necrosis factor inhibitor (TNFi) therapies in individuals with ulcerative colitis (UC).
Fusobacterium nucleatum Extracellular Vesicles Promote Experimental Colitis by Modulating Autophagy via the miR-574-5p/CARD3 Axis
Shuchun Wei, PhD, Jixiang Zhang, PhD, Xiaohan Wu, PhD, Meilin Chen, PhD, Hancheng Huang, PhD, Suqi Zeng, MD, Zixuan Xiang, PhD, Xiangyun Li, PhD, Weiguo Dong, MD, PhD
doi : 10.1093/ibd/izac177
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 9–26
Ulcerative colitis (UC) may be exacerbated by Fusobacterium nucleatum (Fn) infection. However, the mechanism underlying Fn-mediated progression of UC has yet to be established. Here, we aimed to establish whether and how Fn-derived extracellular vesicles (Fn-EVs) participate in the development of experimental colitis through microRNAs (miRNAs).
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
Gary R Lichtenstein, MD, Brian Bressler, MD, Carlos Francisconi, MD, Severine Vermeire, MD, PhD, Nervin Lawendy, PharmD, Leonardo Salese, MD, Gosford Sawyerr, MA, Hongjiong Shi, MSc, Chinyu Su, MD, Donna T Judd, MD, Thomas Jones, MD, Edward V Loftus, Jr, MD
doi : 10.1093/ibd/izac084
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 27–41
In patients with ulcerative colitis (UC), risks of infection and malignancies increase with age. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. This analysis assessed age as a risk factor for adverse events of special interest (AESI) in the tofacitinib UC clinical program.
A Practical Index to Distinguish Backwash Ileitis From Crohn’s Terminal Ileitis in MR Enterography
Bardia Khosravi, MD, Aneseh Salehnia, MD, Neda Pak, MD, S Ali Montazeri, MD, Ali Reza Sima, MD, Homayoun Vahedi, MD, Reza Malekzadeh, MD, Amir Reza Radmard, MD
doi : 10.1093/ibd/izac040
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 42–50
Differentiating ulcerative colitis-associated “backwash� ileitis (BWI) from Crohn’s terminal ileitis (CTI) is a diagnostic challenge and highly affects patient’s management. This study aimed to investigate magnetic resonance enterography (MRE) features including ileocecal valve patency index (ICPI) in patients with BWI and CTI and distinguish these entities based on MRE findings.
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
Marla C Dubinsky, MD, Fernando Magro, MD, Flavio Steinwurz, MD, David P Hudesman, MD, Jami A Kinnucan, MD, Ryan C Ungaro, MD, Markus F Neurath, MD, Nicole Kulisek, MD, Jerome Paulissen, MS, Chinyu Su, MD, Dario Ponce de Leon, MD, Miguel Regueiro, MD
doi : 10.1093/ibd/izac061
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 51–61
Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). These post hoc analyses assessed associations between C-reactive protein (CRP), partial Mayo score (PMS), and efficacy outcomes during tofacitinib induction in UC.
Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis
Maria L Haasnoot, MD, Aart Mookhoek, MD, PhD, Marjolijn Duijvestein, MD, PhD, Geert R A M D’Haens, MD, PhD, Albert J Bredenoord, MD, PhD
doi : 10.1093/ibd/izac044
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 62–69
It has been suggested that eosinophils may be a prognostic marker of disease outcome in ulcerative colitis (UC), but conflicting data exist. The objective was to investigate the extent of mucosal eosinophils and peripheral blood eosinophil count in newly diagnosed UC patients and to investigate its predictive value in short- and long-term disease outcomes.
National Prevalence of Psychological Distress and Use of Mental Health Care in Inflammatory Bowel Disease
Ruby Greywoode, MD, Thomas Ullman, MD, Laurie Keefer, PhD
doi : 10.1093/ibd/izac050
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 70–75
Individuals with inflammatory bowel disease (IBD) have elevated symptoms of anxiety and depression. The burden of such symptoms, accompanied by functional impairment in IBD, is not well documented, nor is utilization of mental health care in this population.
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study
Gaetano Bergamaschi, MD, Fabiana Castiglione, MD, Renata D’Incà , MD, Marco Astegiano, MD, Walter Fries, MD, Monica Milla, MD, Carolina Ciacci, MD, Fernando Rizzello, MD, Simone Saibeni, MD, Rachele Ciccocioppo, MD, Ambrogio Orlando, MD, Fabrizio Bossa, MD, Mariabeatrice Principi, MD, Piero Vernia, MD, Chiara Ricci, MD, Maria L Scribano, MD, Giorgia Bodini, MD, Dario Mazzucco, MD, Gabrio Bassotti, MD, Gabriele Riegler, MD, Andrea Buda, MD, Matteo Neri, MD, Flavio Caprioli, MD, Fabio Monica, MD, Aldo Manca, MD, Erica Villa, MD, Gionata Fiorino, MD, Michele Comberlato, MD, Nicola Aronico, MD, Cristina Della Corte, MD, Roberta Caccaro, MD, Paolo Gionchetti, MD, Paolo Giuffrida, MD, Paola Iovino, MD, Marco V Lenti, MD, Caterina Mengoli, MD, Lucienne Pellegrini, MD, Alberto Pieraccini, MD, Davide Ribaldone, MD, Anna Testa, MD, Cristina Ubezio, PhD, Anna Viola, MD, Maurizio Vecchi, MD, Catherine Klersy, MD, Antonio Di Sabatino, MD RIDART I investigators
doi : 10.1093/ibd/izac054
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 76–84
Anemia is a common extraintestinal manifestation of inflammatory bowel disease (IBD), with a 6% to 74% prevalence and a negative impact on patient survival and quality of life, although the prevalence is apparently declining due to improved disease treatment.
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Kevin L Winthrop, MD, MPH, Séverine Vermeire, MD, PhD, Millie D Long, MPH, Julian Panés, MD, PhD, Siew C Ng, PhD, MRCP, Nicole Kulisek, MD, Rajiv Mundayat, MSc, Nervin Lawendy, PharmD, Ivana Vranic, MD, Irene Modesto, MD, Chinyu Su, MD, Gil Y Melmed, MD, MS
doi : 10.1093/ibd/izac063
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 85
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report herpes zoster (HZ) incidence and risk factors in the tofacitinib UC clinical program (up to 7.8 years).
Psychological Factors Associated With Adherence to Oral Treatment in Ulcerative Colitis
Sonya S Dasharathy, MD, Millie D Long, MD, MPH, Jeffrey M Lackner, PsyD, Dana Ben-Ami Shor, MD, Liu Yang, MD, Nir Bar, MD, Christina Ha, MD, Guy A Weiss, MD
doi : 10.1093/ibd/izac051
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 97–102,
Medication nonadherence in patients with ulcerative colitis (UC) can result in frequent relapses, severe disease, and higher risk of colorectal cancer. Behavioral models relying on motivation and perceived competence, like the self-determination theory (SDT), have been implicated in nonadherence; however, the SDT has not been evaluated in the adult UC population.
The Mechanosensitive Ion Channel PIEZO1 in Intestinal Epithelial Cells Mediates Inflammation through the NOD-Like Receptor 3 Pathway in Crohn’s Disease
Qiuyuan Liu, PhD, Didi Wang, MS, Xiaodong Yang, MD, Fang Ma, MS, Wei Han, PhD, Jing Hu, PhD, Qiao Mei, PhD
doi : 10.1093/ibd/izac152
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 103–115
Crohn’s disease (CD) is an incurable chronic intestinal inflammatory disease with no recognized cause. It has been reported that the mechanosensitive ion channel PIEZO1 initiates proinflammatory responses. However, little is known about the role of PIEZO1 in CD.
Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease
Miikka Höyhtyä, MD, Katri Korpela, PhD, Schahzad Saqib, MSc, Sofia Junkkari, MD, Eija Nissilä, PhD, Anne Nikkonen, RN, Evgenia Dikareva, MSc, Anne Salonen, PhD, Willem M de Vos, PhD, Kaija-Leena Kolho, MD, PhD
doi : 10.1093/ibd/izac182
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 116–124
The role of intestinal microbiota in inflammatory bowel diseases is intensively researched. Pediatric studies on the relation between microbiota and treatment response are sparse.
Searching for a Consensus Among Inflammatory Bowel Disease Studies: A Systematic Meta-Analysis
Lama Izzat Hasan Abdel-Rahman, MSc, Xochitl C Morgan, PhD
doi : 10.1093/ibd/izac194
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 125–139,
Numerous studies have examined the gut microbial ecology of patients with Crohn’s disease (CD) and ulcerative colitis, but inflammatory bowel disease–associated taxa and ecological effect sizes are not consistent between studies.
Is Salt at Fault? Dietary Salt Consumption and Inflammatory Bowel Disease
Rebecca Kuang, BA, Stephen J D O’Keefe, MBBS, MD, MSc, MRCS, FRCP, Claudia Ramos del Aguila de Rivers, MD, Filippos Koutroumpakis, MD, David G Binion, MD
doi : 10.1093/ibd/izac058
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 140–150
Epidemiological trends have led to a growing consensus that diet plays a central role in the etiopathogenesis of inflammatory bowel diseases (IBD). A Western diet high in ultra-processed foods has been associated with an increased prevalence of IBD worldwide.
Appendix and Ulcerative Colitis: a Key to Explaining the Pathogenesis and Directing Novel Therapies?
Nazanin Arjomand Fard, MSc, Heather Armstrong, PhD, Troy Perry, MD, PhD, Eytan Wine, MD, PhD
doi : 10.1093/ibd/izac106
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 151–160,
The vermiform appendix is generally considered a redundant organ, but recent evidence suggests that the appendix could contribute to the pathogenesis of inflammatory bowel diseases, in particular ulcerative colitis (UC), and may even have a therapeutic role; however, mechanisms of the appendix involvement remain unclear.
Bidirectional Correlations Between Health Confidence and Inflammatory Bowel Disease Activity: A Nationwide Longitudinal Cohort Study
Chung Sang Tse, MD, Gil Y Melmed, MD, MS, Corey A Siegel, MD, MS, Chien-Hsiang Weng, MD, MPH, Samir A Shah, MD, S Alandra Weaver, MPH, Brant J Oliver, PhD, MS, MPH, FNP-BC, Glyn Elwyn, MD, PhD, MSc, Welmoed K van Deen, PhD, MD on behalf of IBD Qorus
doi : 10.1093/ibd/izac107
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 161–166
Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases
Catherine Robbe Masselot, PhD, Camille Cordier, PharmD, Benjamin Marsac, MS, Maria Nachury, MD, Renaud Léonard, PhD, Boualem Sendid, PharmD, PhD
doi : 10.1093/ibd/izac244
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 167–171
IBD Journal Editorial Fellowship: A Practical Guide for Future Fellows
Ahmed T Kurdi, MD, Nurulamin M Noor, MRCP, Stephanie L Gold, MD
doi : 10.1093/ibd/izac249
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 172–173
COP27 Climate Change Conference: Urgent Action Needed for Africa and the World: Wealthy nations must step up support for Africa and vulnerable countries in addressing past, present and future impacts of climate change
Lukoye Atwoli, Gregory E Erhabor, Aiah A Gbakima, Abraham Haileamlak, Jean-Marie Kayembe Ntumba, James Kigera, Laurie Laybourn-Langton, Bob Mash, Joy Muhia, Fhumulani Mavis Mulaudzi, David Ofori-Adjei, Friday Okonofua, Arash Rashidian, Maha El-Adawy, Siaka Sidibé, Abdelmadjid Snouber, James Tumwine, Mohammad Sahar Yassien, Paul Yonga, Lilia Zakhama, Chris Zielinski
doi : 10.1093/ibd/izac224
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 174–176,
Bypass of a Duodenal Stricture in Crohn’s Disease Using a Lumen Opposing Metal Stent (LAMS): A Case Report.
Scott Adam Manski, MD, Alexander Schlachterman, MD
doi : 10.1093/ibd/izac192
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 177–178
A Note on Monkeypox for Our Patients With Inflammatory Bowel Disease
Megan Lutz, MD, Mary S Hayney, PharmD, MPH, Francis A Farraye, MD, MSc, Freddy Caldera, DO, MS
doi : 10.1093/ibd/izac214
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 179–180
Correction to: Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease
doi : 10.1093/ibd/izac208
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Page 181
Correction to: Histological Indices and Risk of Recurrence in Crohn’s Disease: A Retrospective Study of a Cohort of Patients in Endoscopic Remission
doi : 10.1093/ibd/izac180
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Page 182
Correction to: Occurrence and Clinical Impact of Eosinophilic Esophagitis in a Large Cohort of Children With Inflammatory Bowel Disease
doi : 10.1093/ibd/izac243
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Page 183
Vedolizumab Therapy for Refractory Eosinophilic Enteritis: A Case of Success
Guilherme Coutinho Martins Mendes Simões, MSc, MD, Verónica Borges, MSc, MD, Carlos Bernardes, MSc, MD, Jaime Ramos, MD
doi : 10.1093/ibd/izac077
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages e1–e2
